SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn’s disease

Abstract

BackgroundAs long-term treatment with anti-tumour necrosis factor (TNF) drugs becomes accepted practice, the risk assessment of prolonged administration requires understanding of anti-TNF long-term safety. Rates of adverse events (AE) in...